Mesenchymal stem cells are propably the most advanced in terms of clinical development of all stem cell types, second only to bone marrow stem cell. This patent covers mesenchymal stem cells in general. Specifically a cell is claimed that is positive for the markers SH2, SH3, and SH4. The claimed cell is capable of differentiating into connective tissue.
Mesenchymal stem cells are very attractive from a clinical development point of view since they can be used in some situations without HLA matching, and also they are able to be administered without immune suppression. Currently there is a Phase III clinical trial ongoing using mesenchymal stem cells for treatment of graft versus host disease.